|
JP2018082720A
|
|
Antibodies to matrix metalloproteinase 9
|
|
AU2016201785A1
|
|
Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor
|
|
JP2016106147A
|
|
Antibodies to matrix metalloproteinase 9
|
|
AU2015203752A1
|
|
Methods and compositions for treatment of pulmonary fibrotic disorders
|
|
AU2015201367A1
|
|
Antibodies to matrix metalloproteinase 9
|
|
AU2014215963A1
|
|
Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
|
|
CA2865501A1
|
|
Antibodies to matrix metalloproteinase 9
|
|
CN103946241A
|
|
Lysyl oxidase-like 2 assay and methods of use thereof
|
|
WO2012155071A1
|
|
Methods of identifying lysyl oxidase - like - 2 (loxl2) binding partners
|
|
WO2012139045A1
|
|
Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
|
|
AP201407907A0
|
|
Antibodies to matrix metalloproteinase 9
|
|
SG10201700568RA
|
|
Antibodies to matrix metalloproteinase 9
|
|
WO2012027721A2
|
|
Antibodies to matrix metalloproteinase 9
|
|
CN103370080A
|
|
Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor
|
|
KR20120091146A
|
|
Methods and compositions for treatment of ocular fibrosis
|
|
NZ625850A
|
|
Methods and compositions for treatment of pulmonary fibrotic disorders
|
|
MX2012002272A
|
|
Catalytic domains from lysyl oxidase and loxl2.
|
|
EP2393923A1
|
|
Methods and compositions for treatment of neovascularization
|
|
EP2185198A1
|
|
Lox and l0xl2 inhibitors and uses thereof
|
